A Phase Ia, Randomized, Double-blind, Placebo-Controlled, Single Ascending Dose Study Evaluating the Safety, Tolerability, and Biological Effects of SYNT001 in Healthy Volunteers

Trial Profile

A Phase Ia, Randomized, Double-blind, Placebo-Controlled, Single Ascending Dose Study Evaluating the Safety, Tolerability, and Biological Effects of SYNT001 in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs SYNT 001 (Primary)
  • Indications Autoimmune disorders; Pemphigus
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Syntimmune
  • Most Recent Events

    • 12 Dec 2017 Status changed from recruiting to completed as the tIgG stopping rule was reached, according to results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 01 Nov 2017 Results presented in an Syntimmune media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top